Drug Pricing Lab Drug Pricing Lab
  • Our Work
  • Learn
  • Tools
  • News
  • About
  • search
search
Sign up for updates
Join our mailing list to receive updates from the Drug Pricing Lab.
Thank you!
Thank you for signing up to receive news and information from the Drug Pricing Lab.
Return to Previous Page

Results for: Payers


Research

Overview of Original Subscription Model and Features of LA and WA Proposals

Here we present our overview of the original subscription-based payment model proposed and the proposals put forth by Louisiana and Washington.
Drug Pricing Lab
January 29, 2019

News

Fact Checking the NYT Fact Check on the Trump Proposal

The Drug Pricing Lab takes issue with The New York Times ‘Fact Check’ on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.
Drug Pricing Lab
December 17, 2018

Research

Spending On Prescription Drugs In The US: Where Does All The Money Go?

Drug Prices
Manufacturers
Market
Our analysis provides an estimate of the revenues or gross profits associated with prescription drugs’ path from the manufacturer to the patient.
Nancy Yu, Preston Atteberry, Peter Bach
August 1, 2018

Research

Value-based pricing concepts laid out

Costs of Care
Drug Prices
Financials/ Profitabililty
In a JAMA Viewpoint, DPL’s Anna Kaltenboeck and Dr. Peter Bach offer a taxonomy of the features that make a payment model truly value-based.
Journal of American Medical Association
May 2, 2018

Research

Value-based pricing vs. outcomes-based contracting

Drug Prices
Outcomes-based contracting
Value-based price
Anna Kaltenboeck and Dr. Peter Bach published commentary in Morning Consult, describing key misconceptions surrounding outcomes-based contracting, and what steps are needed to make the approach value-based.
Drug Pricing Lab
June 21, 2017

Research

Copay Assistance: the Epipen example

Co-Pay Assistance
Co-Payments
Coupons
The DPL uses a real world example of a patient's utilization of Mylan's copay coupon for Epipens to demonstrate the effects of such programs.
Drug Pricing Lab
June 6, 2017

Research

Pricing in the Market for Anticancer Drugs

Manufacturers
Market
Payers
In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States.
American Economic Association
December 13, 2016

Research

Could High Drug Prices Be Bad For Innovation?

Drug Prices
Innovation
Manufacturers
Dr. Peter Bach responds to industry leaders who argue that high prices are necessary for innovation.
Forbes: Cancer
October 23, 2016

News

Copay assistance: Doing more harm than good?

Co-Pay Assistance
Co-Payments
Drug Prices
Dr. Peter Bach discusses how copay assistance programs are actually causing drug prices to rise on Closing Bell.
CNBC
October 12, 2016

Research

Copay Assistance for Expensive Drugs

Co-Payments
Drug Prices
Manufacturers
Dr. Bach argues drug company copay and coupon programs actually play a significant role in keeping prescription drug costs in the U.S. high
Evidence Driven Drug Pricing Project
October 10, 2016

Research

Part B Pilot Congressional Concerns

Medicare
Part B Pilot
Payers
A new analysis reviews payment questions posed by Members of Congress regarding CMS’ proposed Part B drug payment demonstration program.
Memorial Sloan Kettering
May 16, 2016

Research

Overspending driven by oversized single dose vials of cancer drugs

Chemotherapies
Drug Prices
Manufacturers
New analysis in BMJ looks at avoidable excess medicine and waste in top 20 U.S. cancer drugs and how to prevent it
Drug Pricing Lab
May 1, 2016

No Results Found

©Memorial Sloan Kettering Cancer Center, 2019
  • Terms & Conditions
  • Contact
  • MSKCC